|
Avidité Biosciences, Inc. (ARN) Valation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Avidity Biosciences, Inc. (RNA) Bundle
Découvrez le véritable potentiel d'Avidité Biosciences, Inc. (ARN) avec notre calculatrice avancée DCF! Ajustez les hypothèses clés, explorez divers scénarios et évaluez comment les modifications influencent Avidité Biosciences, Inc. (ARN) - le tout dans un modèle d'excel complet.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.8 | 9.3 | 9.2 | 9.6 | 10.9 | 12.4 | 14.0 | 15.9 | 18.1 | 20.5 |
| Revenue Growth, % | 0 | 37.41 | -1.09 | 3.64 | 13.99 | 13.49 | 13.49 | 13.49 | 13.49 | 13.49 |
| EBITDA | -43.8 | -117.4 | -177.5 | -233.5 | -378.9 | -12.4 | -14.0 | -15.9 | -18.1 | -20.5 |
| EBITDA, % | -644.95 | -1258.97 | -1924.61 | -2442.44 | -3477.43 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .4 | .6 | 1.4 | 2.1 | .0 | 1.2 | 1.4 | 1.6 | 1.8 | 2.0 |
| Depreciation, % | 5.5 | 6.85 | 15.04 | 21.98 | 0 | 9.87 | 9.87 | 9.87 | 9.87 | 9.87 |
| EBIT | -44.1 | -118.1 | -178.9 | -235.6 | -378.9 | -12.4 | -14.0 | -15.9 | -18.1 | -20.5 |
| EBIT, % | -650.45 | -1265.83 | -1939.65 | -2464.41 | -3477.43 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 328.1 | 405.5 | 610.7 | 595.4 | 1,501.5 | 12.4 | 14.0 | 15.9 | 18.1 | 20.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.2 | .9 | .0 | 1.1 | .0 | 1.0 | 1.1 | 1.2 | 1.4 | 1.6 |
| Account Receivables, % | 17.68 | 9.65 | 0 | 11.56 | 0 | 7.78 | 7.78 | 7.78 | 7.78 | 7.78 |
| Inventories | -1.2 | -.9 | .0 | .0 | .0 | -.7 | -.8 | -.9 | -1.0 | -1.1 |
| Inventories, % | -17.68 | -9.65 | 0.000010841284 | 0 | 0 | -5.47 | -5.47 | -5.47 | -5.47 | -5.47 |
| Accounts Payable | 7.7 | 2.8 | 4.6 | 8.8 | 8.5 | 8.7 | 9.8 | 11.2 | 12.7 | 14.4 |
| Accounts Payable, % | 114.12 | 30.09 | 50.27 | 92.14 | 77.65 | 70.03 | 70.03 | 70.03 | 70.03 | 70.03 |
| Capital Expenditure | -1.1 | -3.7 | -2.8 | -4.2 | -7.1 | -4.8 | -5.5 | -6.2 | -7.1 | -8.0 |
| Capital Expenditure, % | -16.09 | -40.1 | -30.6 | -44.23 | -64.84 | -39.17 | -39.17 | -39.17 | -39.17 | -39.17 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -43.8 | -117.4 | -173.9 | -235.6 | -378.9 | -12.3 | -13.9 | -15.8 | -17.9 | -20.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -36.7 | -125.5 | -173.5 | -234.7 | -385.2 | -16.0 | -16.9 | -19.2 | -21.8 | -24.7 |
| WACC, % | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 | 8.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -75.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -25 | |||||||||
| Terminal Value | -365 | |||||||||
| Present Terminal Value | -238 | |||||||||
| Enterprise Value | -313 | |||||||||
| Net Debt | -213 | |||||||||
| Equity Value | -100 | |||||||||
| Diluted Shares Outstanding, MM | 112 | |||||||||
| Equity Value Per Share | -0.90 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real Avidity Biosciences (RNA) financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Avidity Biosciences' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as target market size, R&D expenses, and clinical trial timelines.
- Instant Valuation Metrics: Quickly computes intrinsic value, NPV, and other financial indicators.
- High-Precision Accuracy: Leverages Avidity Biosciences' (RNA) actual financial data for dependable valuation results.
- Simplified Scenario Testing: Easily evaluate various hypotheses and analyze different outcomes.
- Efficiency Booster: Streamlines the process, removing the need for intricate valuation models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template with Avidity Biosciences, Inc.'s (RNA) data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Avidity Biosciences, Inc.'s (RNA) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose Avidity Biosciences, Inc. (RNA)?
- Innovative Solutions: Cutting-edge RNA-targeted therapies designed to address unmet medical needs.
- Proven Expertise: A team of industry veterans dedicated to advancing RNA science and technology.
- Robust Pipeline: A diverse portfolio of candidates in various stages of development for multiple indications.
- Commitment to Quality: Adherence to rigorous standards ensures the highest level of safety and efficacy.
- Collaborative Approach: Partnerships with leading organizations to enhance research and development efforts.
Who Should Use This Product?
- Biotech Investors: Develop comprehensive and accurate valuation models for assessing Avidity Biosciences, Inc. (RNA) stock.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights and recommendations for clients interested in Avidity Biosciences, Inc. (RNA).
- Students and Educators: Utilize real-time data to enhance learning and practice in financial modeling within the biotech industry.
- Healthcare Analysts: Gain insights into how innovative biotech companies like Avidity Biosciences, Inc. (RNA) are valued in the market.
What the Template Contains
- Pre-Filled Data: Includes Avidity Biosciences, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Avidity Biosciences, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.